Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sigyn Therapeutics Inc (OP:SIGY)

0.0221 -0.0069 (-23.79%)
Streaming Delayed Price Updated: 1:37 PM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 19,647
Open 0.0242
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0290
Today's Range 0.0221 - 0.0242
52wk Range 0.0103 - 5.000
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Q2 Virtual Investor Summit Presentations Now Available On Demand
From Investor Summit Group
Via ACCESS Newswire
News headline image
Q2 Investor Summit Virtual Live Wednesday June 24
From Investor Summit Group
Via ACCESS Newswire

Performance

YTD
-97.8%
-97.8%
1 Month
-26.3%
-26.3%
3 Month
-43.3%
-43.3%
6 Month
-44.8%
-44.8%
1 Year
-99.4%
-99.4%

More News

Read More
InvestorNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Signs LOI to License CardioDialysis Technology From Sigyn Therapeutics
Via Investor Brand Network
Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE
Via TheNewswire.com
News headline image
Sigyn Therapeutics Launches Initiative to Evaluate Emerging Medical Technologies in Former NFL Players at Risk of CTE
Via NewMediaWire
News headline image
CardioDialysisTM, a Next-Generation Technology to Reduce Major Adverse Cardiovascular Events
Via NewMediaWire
CardioDialysisTM, a Next-Generation Technology to Reduce Major Adverse Cardiovascular Events
Via TheNewswire.com
News headline image
Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases
Via NewMediaWire
Topics Retirement
Scientific American Highlights Scientific Discovery That Supports the Potential Use of CardioDialysis(TM) to Treat Neuroinflammatory Diseases
Via TheNewswire.com
Topics Retirement
News headline image
Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives
Via NewMediaWire
Sigyn Therapeutics Issues Shareholder Update Regarding Potential Merger and Asset Sale Initiatives
Via TheNewswire.com
News headline image
Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
Via NewMediaWire
Sigyn Therapeutics Issues Shareholder Update Highlighting the Advancement of CardioDialysis(TM) and New Corporate Initiatives
Via TheNewswire.com
News headline image
The Emergence of Blood Purification Devices to Treat Cardiovascular Disease
Via NewMediaWire
The Emergence of Blood Purification Devices to Treat Cardiovascular Disease
Via TheNewswire.com
News headline image
Sigyn CEO Note: First-In-Industry Attributes of CardioDialysisTM to Treat Cardiovascular Disease
Via NewMediaWire
Sigyn CEO Note: First-In-Industry Attributes of CardioDialysisTM to Treat Cardiovascular Disease
Via TheNewswire.com
News headline image
Sigyn CEO Note: Nature Publication Reinforces Rationale for CardioDialysisTM to Address Cardiovascular Disease in Dialysis Patients
Via NewMediaWire
Sigyn CEO Note: Nature Publication Reinforces Rationale for CardioDialysisTM to Address Cardiovascular Disease in Dialysis Patients
Via TheNewswire.com
News headline image
Sigyn CardioDialysis(TM) Featured on the Big Biz Show
Via NewMediaWire
Topics Death
Sigyn CardioDialysis(TM) Featured on the Big Biz Show
Via TheNewswire.com
Topics Death
Sigyn Therapeutics Reports Third Quarter Financial Results and Subsequent Introduction of CardioDialysis(TM)
Via TheNewswire.com
Topics Intellectual Property
News headline image
Sigyn Therapeutics Reports Third Quarter Financial Results and Subsequent Introduction of CardioDialysis(TM)
Via NewMediaWire
Topics Intellectual Property
News headline image
Sigyn Therapeutics Releases Shareholder Letter to Introduce CardioDialysis(TM)
Via NewMediaWire
Topics Intellectual Property
Sigyn Therapeutics Releases Shareholder Letter to Introduce CardioDialysis(TM)
Via TheNewswire.com
Topics Intellectual Property

Frequently Asked Questions

Is Sigyn Therapeutics Inc publicly traded?
Yes, Sigyn Therapeutics Inc is publicly traded.
What exchange does Sigyn Therapeutics Inc trade on?
Sigyn Therapeutics Inc trades on the OTC Traded
What is the ticker symbol for Sigyn Therapeutics Inc?
The ticker symbol for Sigyn Therapeutics Inc is SIGY on the OTC Traded
What is the current price of Sigyn Therapeutics Inc?
The current price of Sigyn Therapeutics Inc is 0.0221
When was Sigyn Therapeutics Inc last traded?
The last trade of Sigyn Therapeutics Inc was at 09/11/26 01:37 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.